The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS

References

• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(Suppl 16)15–8
   PubMedGoogle Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449–65
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. The oxygen effect and the tumour microenvironment. Basic Clinical Radiobiology for Radiation Oncologists, GG Steel. Edward Arnold, London 2002; 158–68
   Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels; an adjuvant strategy for radiation therapy. Radiother Oncol 2000; 57: 5–12
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2003; 2(4 Suppl 1)S127–33
   Google Scholar
• National Cancer Institute Website ( www.cancer.gov/clinicaltrials).
   Google Scholar
• Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Met Rev 1990; 9: 267–82
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1518–23
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491–9
   PubMed Web of Science ®Google Scholar
• Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45: 209–11
   PubMedGoogle Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423–35
   PubMed Web of Science ®Google Scholar
• Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 1997; 57: 1829–34
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother Oncol 2001; 60: 155–61
   PubMed Web of Science ®Google Scholar
• Blakey DC, Westwood FR, Walker M, Hughes GD, David PD, Ashton SE, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8: 1974–83
   PubMed Web of Science ®Google Scholar
• Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: Anovel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62: 7247–53
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53: 164–71
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003; 57: 1047–55
   PubMed Web of Science ®Google Scholar
• Ching LM, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6 dimethylxanthenone-4-acetic acid. Cancer Res 1994; 54: 870–2
   PubMed Web of Science ®Google Scholar
• Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 71: 1204–9
   PubMed Web of Science ®Google Scholar
• Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998; 78: 439–45
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Comporative effects of combretastain A-4 disodium phosphate an 5,6-dimethylxanthenon-4-acetic acid on blood perfusion in a murine tumour and normal tissus. Int J Radiat Biol 2001; 77: 195–204
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumor effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001; 17: 508–19
   PubMed Web of Science ®Google Scholar
• Maxwell RJ, Nielsen FU, Breidahl T, Stødkilde-Jørgensen H, Horsman MR. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int J Radiat Oncol Biol Phys 1998; 42: 891–4
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980; 6: 1507–17
   PubMed Web of Science ®Google Scholar
• Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996; 12: 779–89
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Maxwell RJ, Horsman MR, Bentzen SM, Overgaard J. The effect of hypoxia and hyperoxia on nucleoside triphosphate/inorganic phosphate pO2 and radiation response in an experimental tumour model. Br J Cancer 1997; 76: 1432–9
   PubMedGoogle Scholar
• van den Boogaart A, Van Hecke A, Van Huffel P, Graveron-Demilly S, van Ormondt D, de Beer R. MRUI: A graphical user interface for accurate routine MRS data analysis. In: Proceedings of the ESMRMB 13th annual meeting. Prague: 1996. p. 318.
   Google Scholar
• Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995; 63: 119–23
   PubMed Web of Science ®Google Scholar
• Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999; 81: 1318–27
   PubMed Web of Science ®Google Scholar
• Evelhoch JL, LoRusso PM, He Z, DelProposte Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10: 3650–7
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002; 20: 3826–40
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NT, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21: 2831–42
   PubMed Web of Science ®Google Scholar
• Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002; 15: 89–98
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001; 61: 6811–5
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 2002; 15: 99–105
   PubMed Web of Science ®Google Scholar
• Robinson SP, McIntyre DJO, Checkley D, Tessier JJ, Howe FA, Griffiths JR, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88: 1592–7
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001; 156: 503–9
   PubMed Web of Science ®Google Scholar
• McPhail LD, Chung Y-L, Madhu B, Clarke S, Griffiths JR, Kelland LR, et al. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 2005; 11: 3705–13
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Grau C, Horsman MR, Støkilde-Jørgensen H, Overgaard J. Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol 1995; 34: 329–34
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998; 77: 1761–7
   PubMed Web of Science ®Google Scholar
• Raghunand N, Gillies RJ. pH and chemotherapy. The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity, JA Goode, DJ Chadwick. John Wiley and Sons, London 2001; 199–211
   Google Scholar
• Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiol 1977; 123: 511–4
   PubMed Web of Science ®Google Scholar
• Shi W, Horsman MR, Siemann DW. Combined modality approaches using vascular disrupting agents. Vascular-targeted Therapies in Oncology, DW Siemann. John Wiley and Sons, London (in press)
   Google Scholar
• Chaplin DJ, Acker B, Olive PL. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys 1989; 16: 1131–5
   PubMed Web of Science ®Google Scholar
• Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanism of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997; 39: 541–6
   PubMed Web of Science ®Google Scholar
• Dodd NJF, Moore JV, Poppitt DG, Wood B. In vivo magnetic resonance imaging of the effects of photodynamic therapy. Br J Cancer 1989; 60: 164–7
   PubMed Web of Science ®Google Scholar
• Zwi LJ, Baguley BC, Gavin JB, Wilson WR. The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology 1994; 26: 161–9
   PubMed Web of Science ®Google Scholar
• Ferrero E, Villa A, Ferrero ME, Toninelli E, Bender JR, Pardi R, et al. Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996; 56: 3211–5
   PubMed Web of Science ®Google Scholar
• Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 2005; 7: 466–74
   PubMedGoogle Scholar
• Carano RA, Ross AL, Ross J, Williams SP, Koeppen H, Schwall RH, et al. Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med 2004; 51: 542–51
   PubMedGoogle Scholar
• Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of vascular targeting agent in rat tumor model: Dyamic contrast-enhanced versus diffusion-weighted MR imaging. Radiol 2005; 237: 492–9
   PubMed Web of Science ®Google Scholar
• Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003; 76: S60–80
   Google Scholar